Status:
UNKNOWN
Different Doses of vPDT in the Treatment of cCSC
Lead Sponsor:
Peking University People's Hospital
Conditions:
Central Serous Chorioretinopathy
Therapy, Photodynamic
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
This is a prospective, randomized and controlled clinical trial of photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). The patients who met the inclusion criteria were rando...
Eligibility Criteria
Inclusion
- 18-75 years old, regardless of gender;
- Meet the diagnostic criteria of central serous chorioretinopathy;
- The course of CSC (subject to the symptoms of this disease) is more than 3 months;
- Patients with simultaneous diseases of both eyes were included in those with more subretinal fluid.
Exclusion
- macular neuroretinal detachment caused by rhegmatogenous retinal detachment, uveitis, age-related macular degeneration, polypoid choroidal angiopathy and other fundus diseases;
- a previous history of PDT treatment;
- systemic hormone or local hormone nasal spray is being used, or hormone is stopped for less than 3 months.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05390619
Start Date
January 1 2020
End Date
December 31 2023
Last Update
May 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044